[Male contraception].

Contraception masculine.
Condom Contraception Contraception hormonale Contraception thermique Hormonal contraception Indice de Pearl Non-scalpel vasectomy Pearl index Préservatif Thermal contraception Vasectomie sans scalpel

Journal

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie
ISSN: 1166-7087
Titre abrégé: Prog Urol
Pays: France
ID NLM: 9307844

Informations de publication

Date de publication:
Nov 2023
Historique:
received: 23 08 2023
accepted: 04 09 2023
medline: 29 11 2023
pubmed: 28 11 2023
entrez: 28 11 2023
Statut: ppublish

Résumé

Contraception is a major global health issue, which is still dominated by female contraception. Developments in male contraception could help redistribute the contraceptive burden. A literature search was carried out to review the existing options and the criteria for optimal contraception, to establish the principles of a male pre-contraception consultation, and to review the various research avenues with their advantages and disadvantages. The new male contraception options are detailed, whether hormonal (androgen therapy, combination of progestins and testosterone) or non-hormonal, particularly thermal, with current results and avenues for improvement. Condom use and vasectomy remain the only 2 validated options. The recent development of minimally invasive vasectomy without the need for a scalpel and of occlusion techniques has simplified the procedure, minimised the risk of complications (pain, haematomas, post-vasectomy pain syndrome) and improved efficacy. The issues of regret and the possibility of repermeabilisation are also raised. The question of male contraception will become increasingly important in consultations with urologists. The urologist will have to inform the patient, as required by law, before the vasectomy is performed, and provide the best possible advice on the technique, which will often be minimally invasive without the need for a scalpel. New reversible options should also broaden the range of options available on a routine basis, with a view to gradually moving towards contraceptive equity.

Identifiants

pubmed: 38012914
pii: S1166-7087(23)00206-3
doi: 10.1016/j.purol.2023.09.004
pii:
doi:

Substances chimiques

Contraceptive Agents, Male 0
Contraceptive Agents 0

Types de publication

English Abstract Journal Article

Langues

fre

Sous-ensembles de citation

IM

Pagination

718-732

Informations de copyright

Copyright © 2023. Published by Elsevier Masson SAS.

Auteurs

A Faix (A)

Clinique Saint-Roch, 560, avenue du colonel Pavelet dit Villars, 34000 Montpellier, France.

C Methorst (C)

Service de médecine de la reproduction, hôpital des 4 villes, Saint-Cloud, France.

V Hupertan (V)

« Urologie Paris Opéra », cabinet médical, 82, boulevard de Courcelles, 75017 Paris, France.

E Huyghe (E)

Département d'urologie, CHU de Toulouse, hôpital de Rangueil, Toulouse, France; Service de médecine de la reproduction, CHU de Toulouse, hôpital Paule-de-Viguier, Toulouse, France; Inserm 1203, UMR DEFE, université de Toulouse, université de Montpellier, Montpellier, France. Electronic address: eric.huyghe@yahoo.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH